X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Immunome has licensed from Zentalis ZPC-21, a preclinical ROR1 antibody-drug conjugate (ADC) with best-in-class potential on track for IND submission in 1Q 2025, and Zentalis’ proprietary ADC platform technology.
Lead Product(s): ZPC-21
Therapeutic Area: Oncology Product Name: ZPC-21
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Immunome
Deal Size: $310.0 million Upfront Cash: $35.0 million
Deal Type: Licensing Agreement January 08, 2024
Details:
ZN-c3 (azenosertib) is a potentially first-in-class and best-in-class small molecule WEE1 inhibitor in development for the treatment of ovarian cancer and uterine serous carcinoma.
Lead Product(s): ZN-C3,Niraparib Tosylate
Therapeutic Area: Oncology Product Name: ZN-c3
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2023
Details:
Zentalis and Pfizer will initiate a Phase 1/2 dose escalation study of ZN-c3 in combination with encorafenib and cetuximab—an FDA-approved standard of care known as the BEACON regimen—in patients with BRAF V600E-mutated metastatic colorectal cancer (mCRC).
Lead Product(s): ZN-C3,Encorafenib,Cetuximab
Therapeutic Area: Oncology Product Name: ZN-c3
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 24, 2022
Details:
Zentalis intends to use the net proceeds of the offering to help fund ongoing and planned clinical trials, including studies of ZN-c3, its Wee1 inhibitor, and ZN-d5, its BCL-2 inhibitor, and for working capital and general corporate purposes.
Lead Product(s): ZN-C3
Therapeutic Area: Oncology Product Name: ZN-c3
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Financing April 27, 2022
Details:
ZN-c3 showed robust clinical activity in an advanced, sicker patient population (57% had prior pembrolizumab/lenvatinib use), specifically demonstrating a deepening of tumor response, which included one patient who achieved an unconfirmed complete response.
Lead Product(s): ZN-C3,Niraparib Tosylate
Therapeutic Area: Oncology Product Name: ZN-c3
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2022
Details:
ZN-c3 in combination with chemotherapy demonstrated strong anti-tumor activity in a heavily pretreated population, with an ORR of 30.2% across all chemotherapy cohorts, also exhibit a better hematologic and gastrointestinal tolerability profile within Wee1 inhibitor class.
Lead Product(s): ZN-C3,Niraparib Tosylate
Therapeutic Area: Oncology Product Name: ZN-c3
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
Through this partnership, Caris will sequence individuals’ complete exome and transcriptome, leverage real-world data to help inform clinical development and help identify eligible patients for Zentalis’ clinical trials.
Lead Product(s): ZN-C3
Therapeutic Area: Oncology Product Name: ZN-c3
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Caris Life Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 29, 2022
Details:
First patient is dosed for ZN-d5, oral selective BCL-2 inhibitor candidate for hematologic malignances and related disorders, in patients with AL amyloidosis, based on ZN-d5’s optimized, selective design.
Lead Product(s): ZN-D5
Therapeutic Area: Genetic Disease Product Name: ZN-D5
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2022
Details:
SU2C-funded researchers can utilize Zentalis’ ZN-c3 to study the role of Wee1 in tumor growth in depth and use this information to potentially develop new therapeutic strategies utilizing Wee1 inhibition.
Lead Product(s): ZN-C3
Therapeutic Area: Oncology Product Name: ZN-c3
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: SU2C Catalyst
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Funding March 15, 2022
Details:
ZN-c3, a potent and selective WEE-1 inhibitor demonstrates durable clinical activity and good tolerability in varying indications anti-tumor activities in combination with other targeted therapies and overcomes PARP inhibitor resistance.
Lead Product(s): ZN-C3
Therapeutic Area: Oncology Product Name: ZN-c3
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
